SciClone Pharma (SCLN) Tops Q1 EPS by 16c

SciClone Pharma (NASDAQ: SCLN) reported Q1 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $33.6 million versus the consensus estimate of $34 million.

As of March 31, 2015, cash, cash equivalents and short-term investments totaled $96.1 million, compared to $86.3 million as of December 31, 2014. SciClone has a share repurchase program under which its Board of Directors has authorized $80.5 million, of which approximately $68 million had been utilized through March 31, 2015.

For earnings history and earnings-related data on SciClone Pharma (SCLN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15